
    
      PGL4001 will be administered daily to all subjects in an open-label manner with no control
      group. The three months open label treatment period will be followed by a ten day double
      blind treatment with progestin or matching placebo. Subjects will be randomly assigned to
      progestin or matching placebo arm with a 1:1 ratio.
    
  